Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Complications of Diabetes Mellitus

Complications of Diabetes Mellitus

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia due to insulin deficiency, resistance, or both. Prolonged hyperglycemia disrupts metabolic homeostasis and leads to acute and chronic complications.Acute ComplicationsAcute complications result from sudden metabolic imbalance.Diabetic ketoacidosis (DKA) mainly appears in type 1 diabetes but may also develop in type 2 diabetes, particularly under extreme stress. It arises from severe insulin deficiency,...

Diabetic Foot Ulcer

Diabetic Foot Ulcer

Definition A diabetic foot ulcer (DFU) is a chronic, non-healing wound that develops in individuals with diabetes. It typically occurs on pressure-bearing areas such as the heel, metatarsal heads, or hallux, and carries a high risk of infection and amputation.Pathophysiology • The development of DFUs can be explained by four interconnected mechanisms: neuropathy, ischemia, infection, and impaired wound healing. • Neuropathy is the most common factor. Sensory neuropathy reduces pain perception,...

Skin Diseases and Disorders

Skin Diseases and Disorders

Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...

Type I Diabetes II: Pathophysiology

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

Pathophysiology of Diabetes

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...

Type II Diabetes II: Pathophysiology

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).

The British journal of dermatology·2021

Same author

Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021

Same author

Treatment-resistant tinea corporis, a potential public health issue.

The British journal of dermatology·2021

Same author

Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial.

The British journal of dermatology·2020

Same author

Topical crisaborole is an efficacious steroid-sparing agent for treating mild-to-moderate seborrhoeic dermatitis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020

Same author

Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial.

Journal of the European Academy of Dermatology and Venereology : JEADV·2019

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

Protocol to Create Chronic Wounds in Diabetic Mice

Protocol to Create Chronic Wounds in Diabetic Mice

Published on: September 25, 2019

Onychomycosis and diabetes.

S Cathcart¹, W Cantrell, B e Elewski

¹Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, USA. scathcart@uabmc.edu

Journal of the European Academy of Dermatology and Venereology : JEADV

|March 25, 2009

Summary

Diabetic patients with onychomycosis (fungal nail infection) face severe complications. Prompt treatment is crucial, with terbinafine recommended due to fewer drug interactions and high efficacy.

Area of Science:

Dermatology
Podiatry
Infectious Diseases

Background:

Onychomycosis is a common fungal nail infection.
Diabetic patients are at higher risk for severe complications from onychomycosis.
Comorbidities and drug interactions complicate treatment in diabetics.

Purpose of the Study:

To discuss factors specific to diabetic patients in the diagnosis and treatment of onychomycosis.
To evaluate treatment options for onychomycosis in the context of diabetes.

Main Methods:

Literature review and clinical discussion.
Analysis of treatment efficacy and safety profiles.
Consideration of drug-drug interactions and patient comorbidities.

Main Results:

More Related Videos

Come to the Light Side: In Vivo Monitoring of Pseudomonas aeruginosa Biofilm Infections in Chronic Wounds in a Diabetic Hairless Murine Model

Come to the Light Side: In Vivo Monitoring of Pseudomonas aeruginosa Biofilm Infections in Chronic Wounds in a Diabetic Hairless Murine Model

Published on: October 10, 2017

Related Experiment Videos

Last Updated: Jun 24, 2026

Protocol to Create Chronic Wounds in Diabetic Mice

Protocol to Create Chronic Wounds in Diabetic Mice

Published on: September 25, 2019

Come to the Light Side: In Vivo Monitoring of Pseudomonas aeruginosa Biofilm Infections in Chronic Wounds in a Diabetic Hairless Murine Model

Come to the Light Side: In Vivo Monitoring of Pseudomonas aeruginosa Biofilm Infections in Chronic Wounds in a Diabetic Hairless Murine Model

Published on: October 10, 2017

Onychomycosis can lead to severe complications in diabetics, necessitating prompt treatment.
Terbinafine is a preferred treatment due to its efficacy and low risk of drug interactions.
Itraconazole is less favored due to cardiac warnings and drug interactions.

Conclusions:

Prompt treatment of onychomycosis is vital in diabetic patients to prevent severe complications.
Treatment selection requires careful consideration of comorbid conditions and potential drug-drug interactions.
Further research is needed to clarify the role of Candida in diabetic onychomycosis.